Evidence map›Paper›PMID 29590209›Full record

ArticlePloS one2018

Patients with atrial fibrillation and permanent pacemaker: Temporal changes in patient characteristics and pharmacotherapy.

Frederik Dalgaard, Martin H Ruwald, Tommi Bo Lindhardt, Gunnar H Gislason, Christian Torp-Pedersen, Jannik L Pallisgaard

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Frederik DalgaardDepartment of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Hellerup, Denmark.ORCID 0000-0002-7287-4191
Martin H RuwaldDepartment of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Hellerup, Denmark.
Tommi Bo LindhardtDepartment of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Hellerup, Denmark.
Gunnar H GislasonDepartment of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Hellerup, Denmark.
Christian Torp-PedersenDepartment of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Hellerup, Denmark.
Jannik L PallisgaardDepartment of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Hellerup, Denmark.
Gentofte Hospital · DKAalborg University Hospital · DKUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe management of patients with non-valvular atrial fibrillation (NVAF) with rate-lowering or anti-arrhythmic drugs has markedly changed over the last decade, but it is unknown how these changes have affected patients with NVAF with a permanent pacemaker (PPM).

methodsThrough Danish nationwide registries, patients with NVAF and a PPM were identified from 2001 to 2012. Changes in concomitant pharmacotherapy and comorbidities were tested using the Cochran-Armitage trend test and linear regression. Patients with NVAF were identified to calculate the proportional amount of PPM implants.

resultsA total of 12,231 NVAF patients with a PPM were included in the study, 55.6% of which were men. Median age was 78 years (interquartile range 70-84). From 2001 to 2012, the number of NVAF patients with a PPM increased from 850 to 1344, while the number of NVAF patients increased from 67,478 to 127,261. Thus, the proportional amount of NVAF patients with a PPM decreased from 1.3% to 1.1% (p = 0.015). Overall 45.9% had atrial fibrillation (AF) duration less than one year and the proportion declined from 55.5% to 42.4% (p <0.001). Diabetes mellitus increased from 7.2% to 16.8% (p <0.001). Heart failure (HF) decreased from 36.7% to 29.3% (p = 0.010) and ischemic heart disease (IHD) decreased from 32.4% to 26.1% (p <0.001). Beta-blocker use increased from 38.1% to 58.0% (p <0.001), while digoxin and anti-arrhythmic drug use decreased over time.

conclusionFrom 2001 to 2012, the absolute number of NVAF patients with a PPM increased while the proportional amount decreased. The number of NVAF patients receiving a PPM within one year of AF diagnosis decreased. The prevalence of DM increased, while the prevalence of HF and IHD was high but decreasing. The use of beta-blockers increased markedly, while use of digoxin and anti-arrhythmic drugs decreased over time.

Indexed as

Adrenergic beta-AntagonistsAgedAged, 80 and overAnticoagulantsAtrial FibrillationComorbidityDenmarkFemaleHeart FailureHumansMaleMyocardial IschemiaPacemaker, ArtificialRetrospective StudiesRisk FactorsTreatment OutcomeAdrenergic beta-AntagonistsAnticoagulants

Identifiers

PMID29590209
PMCPMC5874078
OpenAlexW2795211122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.